Legend Biotech (LEGN) has released an update.
Legend Biotech has announced the approval of its groundbreaking treatment for multiple myeloma, ciltacabtagene autoleucel (cilta-cel), by China’s National Medical Products Administration. This approval marks a significant advance in the treatment options available for adult patients in China who have not responded to traditional therapies. The decision by the NMPA was influenced by the promising results from Legend Biotech’s Phase 2 clinical study, offering new hope for those battling this challenging form of cancer.
For further insights into LEGN stock, check out TipRanks’ Stock Analysis page.
